Evidence map›Paper›PMID 33932115›Full record

ReviewESC heart failure2021

Iron deficiency in heart failure.

Goran Loncar, Danilo Obradovic, Holger Thiele, Stephan von Haehling, Mitja Lainscak

Open access · goldAbstract readReview
In one paragraph

Review in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Immunometabolism in heart failure.Nature reviews. Cardiology · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Iron Deficiency and All-Cause Hospitalization Risk in a Clinical Cohort of COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Goran LoncarInstitute for Cardiovascular Diseases 'Dedinje', University of Belgrade, Belgrade, Serbia.ORCID 0000-0001-8553-683X
Danilo ObradovicDepartment of Cardiology-Internal Medicine at Heart Center Leipzig, University of Leipzig, Strümpellstraße 39, Leipzig, 04289, Germany.ORCID 0000-0002-2890-5755
Holger ThieleDepartment of Cardiology-Internal Medicine at Heart Center Leipzig, University of Leipzig, Strümpellstraße 39, Leipzig, 04289, Germany.ORCID 0000-0002-0169-998X
Stephan von HaehlingDepartment of Cardiology and Pneumology, University Medicine Göttingen (UMG), Göttingen, Germany.ORCID 0000-0002-9818-042X
Mitja LainscakFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.ORCID 0000-0002-5922-4098
Leipzig Heart Institute · DEUniversitätsmedizin Göttingen · DEUniversity of Belgrade · RSUniversity of Ljubljana · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency is a major heart failure co-morbidity present in about 50% of patients with stable heart failure irrespective of the left ventricular function. Along with compromise of daily activities, it also increases patient morbidity and mortality, which is independent of anaemia. Several trials have established parenteral iron supplementation as an important complimentary therapy to improve patient well-being and physical performance. Intravenous iron preparations, in the first-line ferric carboxymaltose, demonstrated in previous clinical trials superior clinical effect in comparison with oral iron preparations, improving New York Heart Association functional class, 6 min walk test distance, peak oxygen consumption, and quality of life in patients with chronic heart failure. Beneficial effect of iron deficiency treatment on morbidity and mortality of heart failure patients is waiting for conformation in ongoing trials. Although the current guidelines for treatment of chronic and acute heart failure acknowledge importance of iron deficiency correction and recommend intravenous iron supplementation for its treatment, iron deficiency remains frequently undertreated and insufficiently diagnosed in setting of the chronic heart failure. This paper highlights the current state of the art in the pathophysiology of iron deficiency, associations with heart failure trajectory and outcome, and an overview of current guideline-suggested treatment options.

Indexed as

Anemia, Iron-DeficiencyHeart FailureComorbidityHumansIronQuality of LifeIronExercise capacityFerric carboxymaltoseHeart failureIron deficiencyQuality of life

Identifiers

PMID33932115
PMCPMC8318436
OpenAlexW3159632650

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.